



Technical Bulletin

B-Type Natriuretic Peptide (BNP)

TO: Medical Staff and Clients

FROM: Dr. Ana Ortega-Lopez, MD
QMC Lab Director

Dr. Amy Powers, MD
PSC Lab Director
QMC Wahiawa Lab Director

Dr. Wesley Kim, MD
DLS Medical Director

DATE: September 3rd, 2026

SUBJECT: NEW REAGENT: B-type natriuretic Peptide (BNP)

Effective September 28th 2026, Diagnostic Laboratory Services will begin performing B-type natriuretic peptide (BNP) on an updated reagent formulation on the current Beckman chemistry platform. This change will allow us to consolidate instruments, improve TAT (automation), and improve space capacity in the lab to be able to bring in other additional testing.

Method correlation studies between the current and new reagent formulation shows good concordance between the two reagents around the stated cutoff (< 101 pg/mL). As BNP levels increase, there is a slight negative proportional bias between the two reagents with BNP values on the new reagent running slightly lower than the current reagent. For patients being followed clinically with routine BNP testing, physicians may want to consider re-baselining their patients on the new reagent before making therapeutic changes.

Key Updates:

- The new BNP analytical measurement range (AMR) is 5 - 4700 pg/mL
- The reference range remains the same at < 101 pg/mL
- This does NOT affect the proBNP-NT assay which is available at Punchbowl

Please refer to the online test directory for specific collection requirements and stability updates. For information on all of our tests, visit <https://til.dlslab.com/>.

Please refer any questions to Dr. Ana Ortega-Lopez at (808) 691-4470, or DLS Client Services at 589-5101.